CTRI/2019/05/019058Not yet recruitingPhase 4
A Randomised Controlled Trial Of Triphala Ghrita Orally and Triphala Ghrita Netratarpana in Vataja Timira w.r.t.Corneal Astigmatism
Department of Shalakyatantra Government Ayurved College and Hospital Nagpur0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 4
- Status
- Not yet recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1) Patients within age group 18 yrs to 35 with symptoms of Vataja Timira (Corneal Astigmatism) attending OPD of study centers and giving valid informed consent will be included
- •Symptoms are -
- •Aavila Darshana (Diminished Vision)
- •Arunabha Darshana(Slightly reddish looking objects)
- •Vyaviddha Darshana (Distorted visual perception)
- •Bhramativa Darshana (Haloes)
- •Headache (frontal & brow)
- •Watering from eyes
- •2) Patients with corneal astigmatism more than +/- 0.75 D and less than +/- 5.0 D
Exclusion Criteria
- •1) Patients below 18 yrs.
- •and above 35 yrs
- •2) Patients having ocular diseases causing astigmatism like Cataract, Keratoconus,
- •SPK, Pterygium, Glaucoma, Retinal diseases and any ocular surgery.
- •3) Patients having corneal diseases like Corneal Ulcer, Opacity, and Dystrophy.
- •4) Patients with systemic diseases like diabetes, Hypertension and
- •Immunocompromised patients
- •5) Pregnant and Lactating mothers
- •6) Patients with Lenticular Astigmatism & Corneal Astigmatism less than +/- 0.75 D and more than
- •+/- 5.0 D
Investigators
Similar Trials
Not yet recruiting
Not Applicable
A clinical trial of assessment of Internal use of Triphala ghrita and Blood letting by puncturing with 26 number needle in visualization of black spot in front of both eyes.CTRI/2022/02/039904Dr Sandhyarani Tukaram Patil
Not yet recruiting
Phase 2
se of Triphaldi mouthwash along with Triphala churna orally on mouth ulcerCTRI/2022/03/041114Megha Kamble
Not yet recruiting
Phase 2
To study effect of Triphala Kwath in the management of VataraktaCTRI/2021/10/037675Hon Shri Annasaheb Dange Ayurvedic Medical College And Post Graduate Research Centre Ashta
Active, not recruiting
Phase 1
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Triple-Negative Breast Cancer (TNBC) (PRESERVE 2)EUCTR2020-004930-39-ESG1 Therapeutics, Inc.250
Not yet recruiting
Phase 2
To study the effect of Triphala Yog in the management of first degree BurCTRI/2021/12/038755HonShri Annasaheb Dange Ayurvedic Medical college And Post Graduate Reserch Center Ashta